Olema Pharmaceuticals, Inc. reports clinical, corporate, and financing developments as a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other cancers. Olema Oncology updates commonly center on palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, and OP-3136, an orally available KAT6 inhibitor.
Recurring company news covers clinical and preclinical presentations at oncology meetings, endocrine-driven cancer biology, ER+/HER2- breast cancer studies, combination approaches with endocrine therapy and CDK inhibitors, operating results, public offerings, inducement equity grants, and board or management changes.
Olema Oncology (Nasdaq: OLMA) has reported its Q2 2025 financial results and provided key operational updates. The company has selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 trial and the OPERA-02 Phase 3 trial in combination with ribociclib for breast cancer treatment.
Key financial metrics include $361.9 million in cash and equivalents, and a net loss of $43.8 million for Q2 2025, compared to $30.4 million in Q2 2024. R&D expenses increased to $43.9 million, primarily due to a $10 million milestone payment to Aurigene and increased clinical development activities.
The company expects to present mature data from the Phase 1b/2 study at ESMO 2025, initiate OPERA-02 in Q3 2025, and report OPERA-01 top-line data in H2 2026.
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 130,000 shares of common stock with an exercise price of $5.33 per share.
The stock options, approved under the Company's 2022 Inducement Plan, will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 154,500 shares of common stock with an exercise price of $4.37 per share.
The stock options, approved under the company's 2022 Inducement Plan, will vest over four years, with 25% vesting in the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, at 8 a.m. ET in Miami. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.
The company's lead drug palazestrant showed promising results in Phase 1b/2 study, achieving 13.8 months median progression-free survival in combination with ribociclib for ER+/HER2- metastatic breast cancer patients. Two pivotal Phase 3 trials are advancing: OPERA-01 (monotherapy) with top-line data expected in 2026, and OPERA-02 (combination therapy) set to begin in 2025.
Additionally, Olema presented preclinical data for OP-3136, demonstrating anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models. The Phase 1 trial for OP-3136 continues patient enrollment.
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30 p.m. ET in New York, and the T.D. Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 5 p.m. ET in a virtual format. Both presentations will be in a fireside chat format. Live webcasts and recordings will be accessible through Olema's investor relations website at ir.olema.com.
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees. The grants total 104,400 shares of common stock with an exercise price of $5.29 per share, matching the company's last reported sale price on May 1, 2025.
The stock options, approved under Olema's 2022 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remaining portion vesting in 36 monthly installments. The options have a 10-year term and are contingent on continuous employment.
Olema Oncology (OLMA) has revealed promising preclinical data for OP-3136, their novel KAT6 inhibitor, demonstrating significant anti-tumor activity across multiple solid tumor types. The data, presented at AACR 2025, showed effectiveness in ovarian, prostate, and non-small cell lung cancer (NSCLC) models.
Key findings include potent anti-proliferative activity in various cell lines and notable results in xenograft models:
- OVCAR3 (ovarian) model showed sustained tumor regression over 28 days
- LCLC-97TM1 (NSCLC) model demonstrated tumor inhibition comparable to ribociclib
- 22Rv1 (prostate) model exhibited dose-dependent tumor growth inhibition
The company is currently recruiting patients for a Phase 1 trial of OP-3136 as both monotherapy and in combination regimens for multiple solid tumor types.